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 In t r oduc t i on 
 In 2014, the American Cancer Society predicted that nearly 270,000 women in the 
United States would develop breast cancer (BCa) in 2016 1 ; in addition to these new 
cases, the percentage of BCa survivors has increased over the years 1 due to improved 
treatment approaches, making it crucial for dental care providers to be knowledgeable 
concerning the oral health-related consequences of different BCa treatments. 
Depending on the cancer stage and the histologic and molecular profile of the tumor, 2,3 
surgical treatment can be combined with systemic adjuvant therapy to reduce the risk 
of developing distant metastases. 4,5 Systemic therapies include chemotherapy and 
antiestrogen therapy. 6 These therapies are considered either before or after surgery 
based on the patients’ needs. Given that nearly 75% of BCa express estrogen and/or 
progesterone receptors, 7,8 the majority of BCa patients receive either tamoxifen or 
aromatase inhibitors (AIs) (e.g., anastrozole, exemestane, or letrozole 9 ) on a long term 
basis (5–10 years) to decrease the risk of BCa recurrence. 10 
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 A R T I C L E 
Oral health-related concerns, behavior, 
and communication with health care 
providers of patients with breast 
cancer: impact of different treatments
 Oral health-related consequences of 
chemotherapy have been well docu-
mented. 11–13 During conventional 
adjuvant chemotherapy treatments, BCa 
patients reported mucositis, taste 
disturbances, and increased xerostomia. 14 
Oral mucositis was present in approxi-
mately 40% of these patients, with nearly 
half requiring medical intervention, 
including modification of the cytotoxic 
cancer therapy. 15 While extensive 
research concerning the oral 
complications of chemotherapy was con-
ducted and even led to the development 
of guidelines for the management of oral 
mucositis, 16 very few studies so far 
explored oral health complications of 
BCa treatments beyond the chemother-
apy phase of cancer treatment. 
 Recent research showed that AIs—
which severely diminish estrogen 
levels—affect BCa patients’ periodontal 
health and reduce salivary flow, and thus 
impact their oral health-related quality of 
 A B S T R A C T 
 Aim :  The objectives are to compare 
responses of breast cancer (BCa) treat-
ment groups (chemotherapy, tamoxifen, 
and aromatase inhibitors (AIs) to each 
other and a control regarding (a) subjec-
tive oral health, (b) oral health-related 
behaviors, (c) oral health-related con-
cerns, and (d) communication with 
health care providers. 
 Methods :  Survey data were collected 
from 140 postmenopausal BCa patients 
and 41 healthy postmenopausal control 
respondents. 
 Results :  BCa patients reported on aver-
age more frequent mouth sores/
mucositis (5-point scale with 1 = never: 
1.63 vs. 1.14;  p < .01), glossadynia (1.60 
vs. 1.07;  p < .01), xerostomia (2.48 vs. 
1.40;  p < .01), and dysgeusia (2.10 vs. 
1.46;  p < .01) than the control respond-
ents. Patients undergoing chemotherapy 
were more aware that cancer treatment 
can affect their oral health than patients 
on tamoxifen/AI (93% vs. 55%/56%;  p < 
.001). BCa patients reported being more 
frequently informed by oncologists 
about oral health-related effects of 
cancer treatment than by dentists. 
Oncologists/nurses were more likely to 
communicate about oral health-related 
treatment effects with patients undergo-
ing chemotherapy than patients on 
tamoxifen or AIs. Few BCa patients per-
ceived dentists as knowledgeable about 
cancer treatment-related oral concerns 
and trusted them less than oncologists. 
 Conclusions :  BCa treatments impact 
oral health. Low percentages of BCa 
patients had received specific informa-
tion about impacts of BCa treatments on 
oral health from their dentists. 
 KEY WORDS:  breast neoplasms , 
 oral health ,  post menopause , 
 antiestrogen medication ,  chemotherapy 
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life. 17–19 Hyposalivation can increase gin-
gival inflammation and dental caries, and 
may also be responsible for an increased 
prevalence of oral dysesthesia and altera-
tions in taste sensation. 20,21 Many women 
with non-metastatic BCa on AIs receive 
bisphosphonates or other antiresorptives 
such as zolendric acid, ibandronate, or 
more recent, denosumab to prevent 
 cancer treatment-induced bone loss. 3 
Osteonecrosis of the jaw is a rare but 
important adverse event associated most 
often with intravenous bisphosphonates 
or prolonged administration of bone 
inhibitors for the treatment of advanced 
cancer. 22,23 
 In addition, women using antiestro-
gen therapies may experience greater 
levels of depression, musculoskeletal 
symptoms, and fatigue, any of which 
may impact their ability to maintain opti-
mal oral hygiene. 24 However, relatively 
little is known about the oral health-
related effects of BCa patients on 
tamoxifen. 25 A comparison of the oral 
health-related concerns of patients 
treated with conventional chemotherapy, 
tamoxifen, or AIs would therefore clearly 
increase oncologists’, oncology nurses,’ 
and dental professionals’ understanding 
of their role in the prevention, recogni-
tion, and management of oral 
complications of these therapies for BCa 
patients. 
 Research shows that so far oral 
problems were often underdiagnosed by 
physicians and not addressed by 
nurses, 26 and that the implementation of 
an organized plan for oral care was 
relatively often overlooked by the oncol-
ogy team. 27,28 Likewise, a cross-sectional 
survey of dental hygienists in the state of 
Michigan showed that the majority of 
dental hygienists were not aware of oral 
health-related information about dental 
care for BCa survivors. 25 For example, 
while 60%–80% of dental hygienists 
knew that mucosal changes, xerostomia, 
and increased risk for gingival tissue 
change were common oral complications 
of chemotherapy, only 10%–12% were 
aware that oral changes might occur 
when BCa survivors were treated with 
tamoxifen or AIs. 25 Gaining a better 
understanding about which information 
BCa patients treated with chemotherapy, 
tamoxifen, or AIs actually received or 
wanted to obtain from their oncology 
team or dental care provider could be 
crucial to advocate for better oral health-
related support services. 
 Objective 1 of this study is to com-
pare responses related to (a) subjective 
oral health, (b) oral health-related behav-
iors (i.e., tooth brushing, flossing, dental 
visits, and dental products used), and (c) 
oral health-related symptoms of BCa 
patients undergoing conventional chemo-
therapy, tamoxifen, or AIs treatment with 
the responses of postmenopausal control 
respondents. Objective 2 focuses on oral 
concern-related responses of the three 
groups of BCa patients after they had 
received a BCa diagnosis, and specifically 
on the responses of BCa patients on AIs 
concerning their oral health-related expe-
riences in each stage of their previous 
and current cancer therapy. Objective 3 
is to investigate how the three groups of 
BCa patients differed in their responses 
concerning their oral health-related com-
munication with different healthcare 
providers. 
 Me thods 
 Study design and procedures 
 This was a cross-sectional survey of 
women diagnosed with early stage BCa 
who received care at the University of 
Michigan Comprehensive Cancer Center 
(UMCCC) between June 2014 and June 
2015. This study was reviewed and 
determined to be exempt by the 
Institutional Review Board at the 
University of Michigan prior to surveying 
participants (#HUM00089395). 
 Patient selection criteria 
 An a priori power analysis with the 
program package G*Power 3.1.2 ( http://
www.psycho.uni-duesseldorf.de/
abteilungen/aap/gpower3 ) was conducted 
to determine the sample size needed to 
have the power to test hypotheses 
concerning differences in the average 
responses of the three groups of BCa 
patients treated with conventional 
chemotherapy, tamoxifen, or AIs (e.g., 
anastrozole, exemestane, or letrozole) 
and the postmenopausal women in a 
control group. Assuming that we use a 
univariate analysis of variance for the 
comparison of the means of these four 
groups of respondents, that alpha = .05, 
the power = .80, and a large effect size = 
0.40, a minimum of 19 subjects in each 
of the four groups would be needed. 
Data were collected from more than 19 
respondents in each of the four groups. 
 BCa patients who were scheduled to 
receive treatment at the University of 
Michigan Breast Care Center, Ann 
Arbor, Michigan, were approached for 
inclusion in this study. A BCa patient 
was defined as a patient with a 
histologically confirmed diagnosis of 
non-metastatic cancer who was under-
going an active phase of adjuvant BCa 
treatment: conventional chemotherapy, 
or being treated with tamoxifen or 
AI therapy for at least 3 months. The 
recruitment of BCa patients occurred 
during their regularly scheduled medical 
oncology clinic appointments. Trained 
research assistants approached potential 
study subjects in the waiting area of the 
oncology clinics and informed them 
about the study. 
 Control group participants were post-
menopausal women without a cancer 
diagnoses who were recruited from the 
University of Michigan Clinical Study 
website and at the University of 
Michigan—School of Dentistry. Patients 
in both groups were excluded if they had 
less than 20 natural teeth or if for any 
reason they were unable to understand 
the requirements of the study. Only post-
menopausal BCa patients and controls 
were included for this analysis. 
 Questionnaire 
 The questionnaire was created by the 
authors from previously validated ques-
tionnaires 19,27 and was pretested with a 
group of 20 BCa volunteers from 
UMCCC. Based on the feedback from 
this pilot study, the survey was finalized 
and then administered. 
 The 54-item self-administered 
questionnaire assessed (1) respondents’ 
socio-demographic characteristics and 
lifestyle factors (see Table  1 ); (2) 
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 Table 1.  Background- and lifestyle-related characteristics of the respondents in the four groups. 
Background characteristics Chemotherapy 1 N = 28 Tamoxifen N = 52 AI N = 60 Control N = 41 All BCa N = 140 
Age: Mean ± SD Range 58.0 ± 9.9 56.3 ± 8.3 62.5 ± 7.7 66 ± 9.4 59.4 ± 8.8 
 32–78 b * , c *** , g *** 42–79 d *** , e *** 45–78 f * 48–81 h *** 32–79 i *** 
Married or living as married: Yes 61% a ** , g * 89% e *** 77% f *** 51% h *** 78% i *** 
Ethnic/racial background:      
– European American 79% 90% 87% 73% 86% 
– African American 18% 4% 7% 20% 8% 
– Asian American 4% 6% 3% 2% 4% 
– Latina 0% 0% 2% 2% 1% 
– Other 0% 0% 2% 3% 1% 
Years of school:      
– <High school 0% 0% 0% 5% 0% 
– High school 17% 10% 8% 24% 10% 
– Some college 13% 25% 12% 34% 18% 
– 2-yr college degree 15% 8% 13% 12% 11% 
– 4-yr college degree 28% 19% 20% 10% 23% 
– Graduate training 10% 39% e * 47% f *** 15% h ** 39% i *** 
Current employment status:      
– Working full time 43% 33% 38% 10% 31% 
– Working part time 7% 19% 3% 17% 12% 
– Not employed 18% 23% 27% 24% 24% 
– Retired 25% 23% 30% 34% 28% 
– Other 7% c ** 2% e * 2% f ** 15% h * 5% i ** 
Yearly combined family income:      
– $1–$29,999 11% 11% 2% 15% 7% 
– $30,000–49,999 11% 6% 13% 13% 10% 
– $50,000–79,999 26% 26% 32% 25% 29% 
– Over $80,000 52% c ** 57% e ** 54% f *** 46% h *** 55% i *** 
Dental insurance: Yes 82% c * 75% 80% f * 61% 79% i * 
Lifestyle-related behaviors      
Smoking: Yes 4% g * 2% e *** 2% f *** 12% 2% i * 
Alcohol: Yes 67% g *** 64% e ** 78% f ** 32% h *** 71% i *** 
 Note :  * p < .05;  ** p < .01;  *** p < .001. 
 1 Significant differences between specific groups are indicated as follows: 
 a: Significant difference of the “chemotherapy group” (C) versus the “tamoxifen group” (T) responses. 
 b: Significant difference of the “chemotherapy group” versus the “AI group” (A) responses. 
 c: Significant difference of the “chemotherapy group” versus the “control group” (CG) responses. 
 d: Significant difference of the “tamoxifen group” versus the “AI group” responses. 
 e: Significant difference of the “tamoxifen group” versus the “control group” responses. 
 f: Significant difference of the “AI group” versus the “control group” responses. 
 g: Significant difference of the three treatment groups (C vs. T vs. A) responses. 
 h: Significant difference of the four groups (C vs. T vs. A vs. CG). 
 i: Significant difference of the three BCa groups COMBINED versus the “CG” responses. 
subjective oral health indicators as well 
as oral health-related behaviors (i.e., fre-
quency of brushing and flossing, dental 
visits, and dental products used) (see 
Table  2 ); and (3) oral-health symptoms 
including the presence or absence of oral 
problems such as xerostomia, dysgeusia, 
and the perception of oral health impacts 
(see Table  3 and Figure  1 ). In addition, 
BCa patients filled out a survey section 
on perceptions of the effects of cancer 
on oral health and their communication 
with their oncology and dental care 
providers about these issues (see Tables  4 
and  5 ). 
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 Table 2.  Percentages of subjective oral health and oral health-related behavior responses by group 
of respondents. 
Subjective oral health Chemotherapy 1 N = 28 Tamoxifen N = 52 AI N = 60 Control N = 41 All BCa N = 140 
 Health of teeth 2 : 
 – Mean (SD) 
 – Range 
 3.21
(.738) 
 2–4 
 3.65
(1.08) 
 1–5 d *** 
 3.43 
 (.890) 
 1–5  f * 
 2.73 
 (.895) 
 1–5  h *** 
 3.47 
 (.917) 
 1–5  i *** 
 Health of gums 2 : 
 – Mean (SD) 
 – Range 
 3.36 
 (.911) 
 2–5 
 3.48 
 (.980) 
 1–5 
 3.40 
 (.785) 
 2–5 
 2.93 
 (.985) 
 1–5  h * 
 3.42 
 (.882) 
 1–5  i ** 
Amount of saliva:      
 – Too little 
 – Too much 
 – Perfect amount of saliva 
 21% 
 4% 
 75% a * , b ** , g * 
 27% 
 0% 
 73% 
 38% 
 0% 
 62%  d *** 
 20% 
 7% 
 73%  h *** 
 31% 
 1% 
 68%  i * 
Oral health-related behavior 
Frequency of brushing:      
 – Never/rarely 
 – Nearly every day 
 – Every day 
 – More than once a day 
 0/0% 
 0% 
 21% 
 79% 
 0/0% 
 4% 
 17% 
 79% 
 0/0% 
 2% 
 26% 
 72% 
 2/2% 
 11% 
 22% 
 63% 
 0/0% 
 2% 
 22% 
 76% i ** 
Frequency of flossing:      
 – Never 
 – Rarely 
 – Nearly every day 
 – Every day 
 – More than once a day 
 4% 
 18% 
 32% 
 36% 
 10% 
 2% 
 24% 
 31% 
 31% 
 12% 
 0% 
 22% 
 45% 
 30%
3% 
 7% 
 10% 
 29% 
 39% 
 15% 
 1% 
 22% 
 37% 
 32% 
 8% i * 
Last dental visit:      
 – Never 
 – >13 months ago 
 – 7–12 months ago 
 – 4–6 months ago 
 – 0–3 months ago 
 0% 
 4% 
 14% 
 36% 
 46% 
 0% 
 8% 
 12% 
 24% 
 56% 
 0% 
 7% 
 8% 
 30% 
 55% 
 0% 
 20% 
 6% 
 32% 
 44% 
 0% 
 6% 
 11% 
 30% 
 53% i * 
Oral health-related behavior 
Products requested from dentist for:      
 – Mucositis 
 – Halitosis 
 – Xerostomia 
 – Glossadynia 
 4% 
 0% 
 18% b * , c * , g** 
 0% 
 0% 
 2% 
 20% e* 
 4% 
 0% 
 3% 
 29% f* 
 2% 
 0% 
 2% 
 7% h* 
 0% 
 2% 
 3% 
 24% i* 
 3% 
 Note :  * p < .05;  ** p < .01;  *** p < .001. 
 1 Significant differences between specific groups are indicated as follows: 
 a: Significant difference of the “chemotherapy group” (C) versus the “tamoxifen group” (T) responses. 
 b: Significant difference of the “chemotherapy group” versus the “AI group” (A) responses. 
 c: Significant differences of the “chemotherapy group” versus the “control group” (CG) responses. 
 d: Significant difference of the “tamoxifen group” versus the “AI group” responses. 
 e: Significant difference of the “tamoxifen group” versus the “control group” responses. 
 f: Significant difference of the “AI group” versus the “control group” responses. 
 g: Significant difference of the three treatment groups (C vs. T vs. A) responses. 
 h: Significant difference of the four groups (C vs. T vs. A vs. CG). 
 i: Significant difference of the three BCa groups COMBINED versus the “CG” responses. 
 2 The answers range from 1 = “poor” to 5 = “excellent.” 
 Statistical analysis 
 The data were entered into an Excel 
spread sheet (Microsoft), and then exam-
ined for accuracy and completeness. 
They were then imported into SPSS (IBM 
SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp; Released 
2013). Descriptive statistics such as fre-
quency distributions, percentages, 
means, and standard deviations were 
computed to provide an overview of the 
findings. Univariate analyses of variance 
were used to compare the mean answers 
of BCa survivors being treated with 
chemotherapy, tamoxifen or AIs, and the 
control subjects; independent sample 
 t -tests were used to compare the mean 
answers of the combined group of BCa 
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 Table 3.  Participant responses concerning the average frequency of oral symptoms reported 
within the last 3 months. 
In the last 3 months have you had 2 : Chemotherapy 1 N = 28 Tamoxifen N = 52 AI N = 60 Control N = 41 All BCa N = 140 
Mouth sores or mucositis 2.14 ± 1.09 b *** , c *** , g *** 1.65 ± 1.18 e ** 1.36 ± 1.18 1.14 ± 0.42 h *** 1.63 ± 1.04 i ** 
Teeth sensitive to hot, cold, or sweets 1.55 ± 1.01 a * , c * 2.25 ± 1.39 1.93 ± 1.20 2.12 ± 1.14 1.98 ± 1.26 
Glossadynia 2.11 ± 1.33 a *** , c *** , b *** , g *** 1.40 ± 0.86 e ** 1.43 ± 0.96 f * 1.07 ± 0.34 h ** 1.60 ± 1.04 i ** 
Mouth feels dry 2.53 ± 1.42 c * 2.31 ± 1.44 2.60 ± 1.48 f ** 1.70 ± 1.16 h * 2.48 ± 1.46 i ** 
Change in taste 3.57 ± 1.67 a *** , c *** , b *** , g *** 1.84 ± 1.45 1.62 ± 1.20 1.46 ± 0.80 h *** 2.10 ± 1.57 i ** 
Bleeding gums 1.50 ± 1.00 1.78 ± 0.99 1.60 ± 0.96 1.84 ± 0.94 1.65 ± 0.98 
Aching in mouth, teeth, or jaw 1.50 ± 0.96 1.42 ± 0.76e * 1.57 ± 1.05 1.82 ± 1.11 1.50 ± 0.94 
Bad breath 1.67 ± 1.09 1.88 ± 0.96 1.95 ± 1.11 2.02 ± 0.97 1.87 ± 1.05 
 Note :  * p < .05;  ** p < .01;  *** p < .001. 
 1 Significant differences between specific groups are indicated as follows: 
 a: Significant difference of the “chemotherapy group” (C) versus the “tamoxifen group” (T) responses. 
 b: Significant difference of the “chemotherapy group” versus the “AI group” (A) responses. 
 c: Significant differences of the “chemotherapy group” versus the “control group” (CG) responses. 
 e: Significant difference of the “tamoxifen group” versus the “control group” responses. 
 f: Significant difference of the “AI group” versus the “control group” responses. 
 g: Significant difference of the three treatment groups (C vs. T vs. A) responses. 
 h: Significant difference of the four groups (C vs. T vs. A vs. CG). 
 i: Significant difference of the three BCa groups COMBINED versus the “CG” responses. 
 2 Answers range from 1 = “Never”, 2 = “Hardly ever”, 3 = “On occasion”, 4 = “Fairly often” to 5 = “Very often.” 
 Figure 1.  Respondents currently on AI: oral health impacts in each stage of treatment.  Oral health 
impact was assessed by adding 1 point for reporting to have had mouth sores or mucositis; teeth 
sensitive to hot, cold, or sweets; glossadynia; dry mouth; change in taste; bleeding gums; aching 
in mouth, teeth, or jaw; and bad breath. The scores can range from 0 to 8 (8 = highest impact). 
0
0.5
1
1.5
2
2.5
Pre-Surg Surgical Chemotherapy Tamoxifn AI
Oral Health Impact for Each Stage of Treatment for 
Respondents Currently on AIs
patients and of the control group 
respondents. In addition, post hoc com-
parisons were conducted to compare the 
responses of sub groups of respondents, 
namely “chemotherapy group” versus 
“tamoxifen group” responses, “chemo-
therapy group” versus “AI group” 
responses, “tamoxifen group” versus “AI 
group” responses, responses of the three 
treatment groups, and responses of each 
treatment group versus the control 
group. Chi-squared tests were used to 
test relations between categorical 
variables. The significance level was set 
at  p < .05. 
 Resu l t s 
 A total of 300 patients with early stage 
BCa receiving either adjuvant chemo-
therapy or endocrine therapy (tamoxifen 
or AIs) for at least 3 months for BCa 
were approached for inclusion. Of these 
women, 263 agreed to participate (87%). 
The current analyses were restricted to 
181 women who were postmenopausal 
and had completed questionnaires 
(65%). Data were collected from 28 BCa 
patients receiving adjuvant chemother-
apy, 52 patients being treated with 
tamoxifen, 60 women being treated with 
AIs, and 41 women in a control group 
without any cancer diagnoses. Table  1 
provides an overview of the background 
characteristics (a) for the four groups 
(3 cancer groups and the control group) 
as well as (b) for the combined group of 
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 Table 4.  Percentages of oral health concerns responses of BCa respondents .
Oral concern-related responses: % Yes Chemotherapy 1 N = 28 Tamoxifen N = 52 AI N = 60 
Problems with teeth or gums since diagnosis 21% 20% 25% 
Do you believe your oral health problem is related to your cancer treatment? 30% a *** 23% 30% 
Are you aware that cancer treatment may affect oral health? 93% a ** , b *** 55%  56%  d *** 
Who told you that cancer treatment may affect oral health?    
 – Primary care 
 – Nurse practitioner 
 – Oncologist 
 – Dental provider 
 – Other 
 – No one 
 0% 
 7% 
 60% a *** , b*** 
 25% 
 6% 
 2% a ** , b *** 
 0% 
 5% 
 34% 
 24% 
 2% 
 35% 
 0% 
 10% 
 32%  d*** 
 25% 
 4% 
 44% 
Was there a time when you wanted to visit your dentist but could not because of 
your BCa treatment? 
29% 22% 24% 
Point of treatment at which your dentist discussed impacts of cancer treatment on oral health: 
 – Presurgical 
 – Chemotherapy 
 – Radiation 
 – Antiestrogen 
 – Never discussed 
 – Have not visited dentist since diagnosis 
 24% a * , d ** 
 14% 
 0% a * , b** 
 0% a ** , d** 
 16% a ** , b ** , c** 
 46% a ** , b ** 
 8% 
 12% 
 15% 
 18% 
 45% 
 10% 
 14% 
 4% 
 14% 
 14% 
 52% 
 8% 
 Note :  * p < .05;  ** p < .01;  *** p < .001. 
 1 Significant subgroup differences are indicated as follows: 
 a: Significant difference of the “chemotherapy group” versus the “tamoxifen group” responses. 
 b: Significant difference of the “chemotherapy group” versus the “AI group” responses. 
 c: Significant difference of the “tamoxifen group” versus the “AI group” responses. 
 d: Significant difference of the three treatment groups responses. 
 Table 5.  Responses related to oral health-related patient–provider interactions. 
Providers’ oral health-related behaviors Chemotherapy 1 N = 28 Tamoxifen N = 52 AI N = 60 
Oncologist/nurse asked about your oral health? Yes 83% a ** , b ** , d *** 32% 33% 
Oncologist/nurse asked about mouth sores or dry mouth? Yes 92% a ** , b ** , d *** 36% c * 44% 
Dental providers asked if oral health has changed during cancer treatment:    
 – Yes 
 – No 
 – “I have not been to dentist since diagnosis” 
 23% 
 31% 
 46% a ** , b ** , d * 
 50% 
 40% 
 10% c ** 
 44% 
 48% 
 8% 
Patient oral health-related responses to providers: % Yes Chemotherapy N = 28 Tamoxifen N = 52 AI N = 60 
Confident to ask medical provider about oral problems? 94% 96% 98% 
Confident to ask nurse about oral problems? 94% b * 88% 98% 
Comfortable asking dental provider about oral problems? 86% b * , d * 82% c * 96% 
Patients’ perception of provider’s oral-health knowledge Chemotherapy N = 28 Tamoxifen N = 52 AI N = 60 
Oncologist/nurse is knowledgeable about oral problems? Yes 100% a * , b * 89% 95% 
Dental provider is knowledgeable about oral health needs during my cancer treat-
ment? Yes 
70% 65% 53% 
Patients’ confidence that dental provider can answer oral health/cancer treatment-
related concerns: Yes of confident/very confident 
65% d * 56% c * 52% 
 Note :  * p < .05;  ** p < .01;  *** p < .001. 
 1 Significant subgroup differences are indicated as follows: 
 a: Significant difference of the “chemotherapy group” versus the “tamoxifen group” responses. 
 b: Significant difference of the “chemotherapy group” versus the “AI group” responses. 
 c: Significant difference of the “tamoxifen group” versus the “AI group” responses. 
 d: Significant difference of the three treatment groups responses. 
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BCa patients versus the control respond-
ents. BCa patients were on average about 
7 years younger than the control subjects 
(59.4 years vs. 66 years;  p < .001) and 
were more likely to be married or living 
as married ( p < .001) than the control 
respondents; they were significantly 
better educated ( p < .05), were more 
likely to work full time ( p < .01), and 
had a higher yearly combined family 
income ( p < .001). BCa patients were 
also less likely to smoke ( p < .05), 
but more likely to consume alcohol 
( p < .001) compared to the control 
subjects. When comparing the three 
BCa groups, women undergoing chemo-
therapy were younger, smokers, and less 
likely to be married than either 
Tamoxifen or AI participants. Also 
women on AI treatment were signifi-
cantly more likely to consume alcohol 
as compared to women undergoing 
chemotherapy or using tamoxifen 
(78% vs. 67% vs. 64%;  p < .001). 
 Table  2 provides an overview of the 
responses related to respondents’ 
subjective oral health and oral health-
related behavior. On average, the control 
group reported poorer mean health of 
teeth (scale from 1 = poor to 5 = excel-
lent: 2.73 vs. 3.47;  p < .001) and poorer 
mean health of their gums (2.93 vs. 3.42; 
 p < .05) than the three groups of BCa 
patients combined. BCa patients were 
more likely to report having too little 
saliva than the control group (31% vs. 
20%;  p < .05). However, when the three 
BCa patient groups were compared in 
regard to their amount of saliva, the AI 
group was significantly more affected 
with xerostomia than the tamoxifen and 
the chemotherapy groups. 
 Compared to the control group 
subjects, BCa patients were more 
likely to brush more than once a day 
( p < .01), but less likely to floss fre-
quently ( p < .05). BCa patients were 
more likely to have had a dental visit in 
the recent past (53% vs. 44%,  p < .05) 
than the control respondents. AI users 
were more likely to have asked their 
dental provider for products related to 
xerostomia(29% vs. 18% vs. 20%; 
 p < .01) than chemotherapy or 
tamoxifen respondents. 
 Table  3 provides an overview of the 
average frequency of oral symptoms 
within the last 3 months by type of 
cancer treatment versus being a control 
group respondent. These data show that 
BCa patients reported more frequent 
problems with mouth sores/mucositis 
(scale from 1 = “never” to 5 = “very 
often”: 1.63 vs. 1.14;  p < .01), oral 
dysesthesia (1.60 vs. 1.07;  p < .01), with 
xerostomia (2.48 vs. 1.70;  p < .01), and 
having experienced dysgeusia (2.10 vs. 
1.46;  p < .01) than the control group 
respondents. In addition, this table also 
shows that respondents in the three BCa 
patient sub groups differed in the average 
frequencies with which they reported 
some of these symptoms. For example, 
while chemotherapy group members did 
not differ significantly from tamoxifen 
group members in the average frequency 
of mouth sores/mucositis, these two 
groups differed from the AI group and 
the control group respondents. 
 When BCa patients currently treated 
with AIs were asked during which stage 
of treatment their oral health had been 
most impacted, they reported the greatest 
mean impact was nearly 2 times greater 
when taking AI, as compared to the 
other treatments taken during chemo-
therapy (see Figure  1 ). 
 Table  4 provides an overview of oral 
concerns in each of the three BCa treat-
ment groups since their BCa diagnosis. 
Between 20% and 25% of the respond-
ents in these three groups indicated that 
they had a problem with their teeth and 
gums since the BCa diagnosis. 
Chemotherapy and AI group respondents 
as compared to tamoxifen respondents 
were more likely to report that they 
believed that their oral health problems 
were related to their cancer treatment 
( p < .01). BCa patients on chemotherapy 
were significantly more likely to be aware 
that their cancer treatment can affect 
their oral health than patients on tamox-
ifen (93% vs. 55%;  p < .01) and patients 
on AI (93% vs. 56%;  p < .001). When 
asked who told them that their cancer 
treatment can affect their oral health, 
none of the respondents indicated their 
primary care provider and only a 
small percentage of respondents (7% 
chemotherapy; 5% tamoxifen; 10% AI) 
reported that nurse practitioners had 
informed them. A significantly higher 
percentage of BCa patients undergoing 
chemotherapy were informed by their 
oncologist about oral health-related 
consequences compared to patients on 
tamoxifen (60% vs. 34%;  p < .001) and 
patients on AI (60% vs. 32%;  p < .001). 
Only 25% of chemotherapy patients, 24% 
of tamoxifen patients, and 25% of AI 
patients indicated that their dentist had 
shared with them that their cancer 
treatment can impact their oral health. 
Overall, only 2% of patients undergoing 
chemotherapy, but 35% of patients on 
tamoxifen and 44% of patients on AIs 
had not been informed about the impact 
of BCa treatment on oral health. 
 Under 30% of patients in each of the 
three groups reported that they had 
wanted to visit their dentist but could 
not do so due to their BCa treatment 
(chemotherapy: 29%; tamoxifen: 22%; 
AI: 24%). When BCa respondents were 
asked at which time their dentists had 
discussed oral health-related effects of 
their cancer treatments, 52% of patients 
on AIs, 45% of patients on tamoxifen, 
and 16% of patients undergoing chemo-
therapy reported that their dentist had 
never discussed the potential treatment 
effects on their oral health. However, 
while nearly one in four patients under-
going chemotherapy reported that their 
dentist had discussed these impacts on 
their oral health at dental visits, a signifi-
cantly lower percentage of patients on 
tamoxifen had been informed at that 
time (24% vs. 8%;  p < .05). In addition, 
the data showed that only 14% of the AI 
group respondents and 18% of the 
tamoxifen respondents had any discus-
sion with their dentists about oral health 
effects of antiestrogen therapy. 
 Table  5 reports the BCa patients’ 
responses to oral health-related patient–
provider interactions by type of 
treatment. The BCa patients reported that 
their oncologists as well as oncology 
nurses were more likely to ask them 
about their oral health and about 
mucositis or xerostomia when 
undergoing chemotherapy than when 
being treated with tamoxifen or AIs. 
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Respondents were surveyed as to 
whether their dentists had asked them if 
they thought their oral health had 
changed during cancer treatment, 50% of 
patients on tamoxifen, 44% of patients 
on AI, and 23% of patients undergoing 
chemotherapy reported that their dentist 
had asked them this question about their 
oral health. There were no significant 
differences between the groups in terms 
of the respondents’ reported confidence 
in asking their oncologist or oncology 
nurse or their dental provider about oral 
health problems. When asked about the 
respondents’ perceptions of their 
oncologist’s/nurse’s oral health-related 
knowledge, 100% of the chemotherapy 
group respondents versus only 89% of 
the tamoxifen group ( p < .05) and 95% 
of the AI group respondents ( p < .05) 
thought that these providers were 
knowledgeable. In contrast, only 70% of 
BCa patients undergoing chemotherapy 
indicated that their dental provider was 
knowledgeable about oral health 
problems related to BCa treatment 
(chemotherapy vs. tamoxifen vs. AI: 70% 
vs. 65% vs. 53%;  p < .05). In addition, 
65% of patients undergoing chemother-
apy versus only 56% of patients in the 
tamoxifen group and 52% of patients in 
the AI group were confident/very 
confident that their dental provider could 
answer questions related to oral health-
related issues of cancer patients. 
 D i s cus s i on 
 This study assessed BCa patients in 
three different treatment conditions and 
a control group of healthy postmeno-
pausal women regarding their subjective 
oral health, oral health-related symp-
toms, dental health behaviors, and 
communication with health care provid-
ers. The data show that while BCa 
patients had high dental utilization, 
they nevertheless had serious oral 
health concerns and symptoms. Another 
important finding is that BCa patients, 
especially those on antiestrogen medica-
tions, did not consider their dentists to 
be knowledgeable about oral health-
related effects of cancer treatments and 
were not confident in their dental care 
providers to answer their oral health/
cancer treatment-related concerns. 
 Regarding the comparability of the 
three BCa patient groups and the control 
group, it is important to note that the 
control group respondents were on aver-
age 7 years older and thus more likely to 
be retired—which might have contrib-
uted to having a lower income and being 
less likely to have dental insurance than 
the BCa patients. These differences might 
explain why the control group respond-
ents were less likely to have had a dental 
visit in the recent past, and had poorer 
self-reported mean dental health and per-
iodontal health than the BCa patients. 
However, it should not have affected how 
often they engaged in oral hygiene-
related behavior. It is therefore surprising 
that the control group subjects brushed 
on average less frequently than the BCa 
patients. The finding that BCa patients 
had on average better subjective dental 
and periodontal health than the control 
respondents could therefore not only be 
related to their higher dental care utiliza-
tion, but also to their improved oral 
hygiene behavior. However, one addi-
tional explanation for these improved 
subjective dental health reports of BCa 
patients could be an argument provided 
by Taichman  et al. These authors also 
found that women with a BCa diagnosis 
perceived their oral health more posi-
tively than women without such a 
diagnosis. 29 They explained this finding 
by arguing that women with a potentially 
life-threatening cancer diagnosis might 
consider oral health-related problems as 
less important and thus evaluate their 
seriousness lower. 
 While BCa patients had on average 
better subjective dental and periodontal 
health than the control respondents, 
they reported more frequent oral symp-
toms such as mouth sores/mucositis, 
glossadynia, dysgeusia, and xerostomia 
within the last 3 months than the con-
trol group respondents. An analysis of 
the differences in the average frequen-
cies of reported symptoms among the 
three BCa groups helps to understand 
the treatment specific concerns. BCa 
patients undergoing chemotherapy 
reported more frequent mouth sores/
mucositis, glossadynia, xerostomia, and 
dysgeusia than the control group 
respondents, but they also reported more 
glossadynia and dysgeusia than patients 
on tamoxifen and more mouth sores/
mucositis, glossadynia, and dysgeusia 
than patients on AIs. The only symptom 
reported on average less frequently by 
patients undergoing chemotherapy com-
pared to patients on AIs and the control 
group patients is teeth sensitivity to hot, 
cold, or sweets. A comparison of the 
responses of BCa patients on tamoxifen 
versus AIs showed that there were no 
significant differences between these two 
groups. 
 The high frequency of oral impacts 
replicated previous results with patients 
undergoing chemotherapy 15,16 and offer 
more insight into the subjective oral 
health perceptions of AI users. However, 
given that there is relatively little known 
about the oral health-related effects of 
BCa patients on tamoxifen, 25 the findings 
that BCa patients on tamoxifen reported 
more mouth sores/mucositis and glossa-
dynia as a consequence of their treatment 
than the control group respondents is 
definitely noteworthy and deserves future 
research efforts. 
 Regarding the oral health-related 
symptoms of AI users, the data showed 
that a higher percentage of these patients 
reported xerostomia than BCa patients 
undergoing chemotherapy (38% vs. 21%; 
 p < .05) and the control group respond-
ents (38% vs. 20%;  p < .05). Given that 
saliva is vital to overall oral health 
because a lack of saliva is associated 
with increased caries and other oral 
health impacts, 20,21 this finding needs to 
be communicated to health care provid-
ers interacting with BCa patients on AIs 
and should be followed up in future 
studies. 
 An additional sub group analysis of 
only the responses of BCa patients cur-
rently on AIs concerning the oral health 
impact during each stage of treatment 
provides additional insights into the 
effects of AIs on patients’ oral health. 
Figure  1 clearly shows that the average 
sum of oral health impacts, namely of 
mouth sores/mucositis, teeth sensitive to 
hot, cold, or sweets, glossadynia, dry 
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Breast  cancer  pat ients ’  ora l  hea l th
mouth, change in taste, bleeding gums, 
aching in mouth, teeth, or jaw, and bad 
breath was highest during current use of 
AIs and not during the times in which 
they had undergone chemotherapy or 
were on tamoxifen. 
 Another important finding of this 
study was the responses related to 
providers’ oral health-related behaviors 
and the patients’ perceptions of the pro-
viders’ oral health knowledge. BCa 
patients indicated that oncologists/nurses 
did ask about oral health issues. This 
finding is in contrast to previous litera-
ture showing that oral health is often 
overlooked at the oncology visit. 30 
However, given that BCa survivors 
reported that oncologists were most 
likely to discuss oral health-related issues 
with patients undergoing chemotherapy, 
educational efforts may be needed to 
inform them that patients in this subjec-
tive survey undergoing AI therapy 
reported even more severe oral health 
consequences than patients undergoing 
chemotherapy. 
 Interestingly, low percentage of BCa 
patients reported that dentists had asked 
them about oral health-related effects of 
their cancer treatments at the various 
stages of treatment. Furthermore, not all 
BCa patients were confident/very confi-
dent that dental care providers can 
answer their oral health/cancer treat-
ment-related concerns, with patients on 
AIs showing the least confidence (chem-
otherapy 70%; tamoxifen 65%; AI 53%) 
and considering them as least 
knowledgeable(chemotherapy 65%; 
tamoxifen 56%; AI 52%) about oral 
health-related effects of cancer treat-
ments. While these findings merely 
reflect patients’ subjective perceptions of 
their dental care providers’ knowledge 
and communication efforts, they should 
nevertheless be taken as an indication 
that future research is needed concerning 
dental care providers’ expertise and pro-
fessional behavior in this domain. These 
findings along with previous results 
concerning dental hygienists’ lack of 
awareness of the oral impacts of AI 23 
point to the urgency to increase educa-
tional efforts for dental care providers in 
general. 
 Patient–provider communication 
deserves additional attention because 
BCa patients should receive inter-
professional care in which all providers 
such as oncologists, nurse practitioners, 
primary care physicians, and dental care 
providers, namely dentists and dental 
hygienists, collaborate and assure that 
BCa patients receive the preventive, diag-
nostic, and treatment-related oral health 
care that will allow them to maintain 
good oral health and have excellent oral 
health-related quality of life. Assuring 
that medical and dental school curricula 
inform future providers about these 
issues and offering continuing education 
courses about these topics is therefore 
crucial. Additional patient education 
efforts are needed as well. 
 This study had several limitations. 
One potential limitation is a primary 
reliance on self-reported data. Future 
research could include oral examinations 
to assess, for example, the degree to 
which patients suffered from xerostomia 
or mucositis. However, the questionnaire 
measures were pilot tested and had pre-
viously been validated. Another 
limitation is the fact that budgetary 
restrictions only allowed to conduct a 
study with a sample size suited to detect 
medium to large effects. Yet, given the 
importance of this topic, future research 
should aim to collect data from larger 
samples to allow the identification of 
even small effect sizes plus comparisons 
of subgroups of patients in each treat-
ment condition. For example, while we 
did not collect data concerning previous 
cancer treatments, it would be helpful to 
compare responses of patients on AIs 
who had been previously treated with 
tamoxifen versus those who had not 
undergone such treatment in future 
research. Additionally, we did not con-
sider the effects of prior exposure to 
bisphosphonates on BCa patients’ sub-
jective oral health and oral health 
concerns. Finally, our sample was not 
ethnically diverse. Future research 
should include sufficient number of 
patients from diverse backgrounds. 
 In conclusion, this study carefully 
documented that BCa patients undergo-
ing chemotherapy, or being on tamoxifen 
and AI frequently experience serious oral 
health concerns. The finding that BCa 
patients reported that medical and dental 
care providers did not routinely inform 
them about potential treatment-related 
oral health issues and ask them about 
current oral health concerns calls for 
increased educational efforts to assure 
that these providers have the knowledge 
to provide the best possible care for these 
patients in the future. Research should 
also investigate whether these findings 
are applicable to cancer patients from 
diverse backgrounds, individuals with 
metastasized disease, and cancer patients 
at other points in the treatment 
trajectory. 
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